ImmunityBio Gets First Anktiva Authorization in Asia
By Kelly Cloonan
ImmunityBio received regulatory approval for its Anktiva drug in Macau, marking the treatment's first authorization in Asia.
The biotechnology company said Friday the Pharmaceutical Administration Bureau of the Macau Special Administrative Region of the People's Republic of China granted the approval for Anktiva in combination with Bacillus Calmette-Guérin for adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
The approval follows a review that considered prior regulatory decisions by the Food and Drug Administration and the European Medicines Agency, the company said.
The approval reflects ImmunityBio's plans to expand internationally. The company said it continues to engage with additional health authorities across the Asia-Pacific region and is beginning to prepare for potential commercial distribution.
"Our focus is on executing this expansion in a disciplined manner, building on our existing approvals to support long-term global access for patients," Chief Executive Richard Adcock said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
March 20, 2026 13:49 ET (17:49 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States